Page last updated: 2024-11-06

ro 22-3581

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID82316
CHEMBL ID528463
SCHEMBL ID611481
MeSH IDM0106209

Synonyms (64)

Synonym
AC-3232
SDCCGMLS-0066010.P001
4'-(imidazol-1-yl)acetophenone, 96%
1-(4-imidazol-1-yl-phenyl)-ethanone
smr000420252
MLS000780069 ,
ro 22-3581
TCMDC-125536 ,
CHEMBL528463
4'-(1h-imidazol-1-yl)acetophenone
10041-06-2
STK865696
1-[4-(1h-imidazol-1-yl)phenyl]ethanone
AB00443701-03
1-(4-imidazol-1-ylphenyl)ethanone
AKOS000120316
A800197
tetrahydrofuran-3-carboxylic acid;4'-(1-imidazolyl)acetophenone
NCGC00246456-01
1-(4-acetylphenyl)imidazole
4'-(imidazol-1-yl)acetophenone
4'-(imidazol-1-yl)methyl phenyl ketone
unii-kqu6es7dss
einecs 233-123-5
kqu6es7dss ,
4'-(1-h-imidazole-1-yl)acetophenone
4-(1-imidazolyl)acetophenone
1-[4-(1h-imidazol-1-yl)phenyl]ethan-1-one
GEO-01576
4-(imidazol-1-yl)acetophenone
HMS2796H07
F0290-1071
1-(4-(1h-imidazol-1-yl)phenyl)ethanone
FT-0616787
SCHEMBL611481
10A-004
mfcd00005282
SY004866
4 inverted exclamation mark -(1-imidazolyl)acetophenone
1-[4-(1-imidazolyl)phenyl]ethan-1-one
ethanone, 1-[4-(1h-imidazol-1-yl)phenyl]-
1-[4-(1h-imidazol-1-yl)phenyl]ethanone #
W-200067
J-640087
1-[4-(1h-imidazol-1-yl)phenyl]-1-ethanone
4'-(1-imidazolyl)acetophenone
ethanone, 1-(4-(1h-imidazol-1-yl)phenyl)-
4'-(imidazol-1-yl) acetophenone
DTXSID50143259
us9138393, 4?-(imidazol-1 yl) acetophenome
us9144538, 4'-(imidazol-1yl) acetophenome
bdbm181114
J-800090
4`-(1h-imidazol-1-yl)acetophenone
(+)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazolemaleate
AC1221
1-(4-(1-imidazolyl)phenyl)ethan-1-one
1-(4-(1h-imidazol-1-yl)phenyl)ethan-1-one
imidazolacetophenone
EN300-17258
HY-109877
CS-0034130
4/'-(imidazol-1-yl)acetophenone
Z56899206
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency3.54810.003245.467312,589.2998AID2517
Chain A, Ferritin light chainEquus caballus (horse)Potency4.46685.623417.292931.6228AID485281
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
chromatin remodelingBromodomain adjacent to zinc finger domain protein 2BHomo sapiens (human)
regulation of transcription by RNA polymerase IIBromodomain adjacent to zinc finger domain protein 2BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
DNA bindingBromodomain adjacent to zinc finger domain protein 2BHomo sapiens (human)
protein bindingBromodomain adjacent to zinc finger domain protein 2BHomo sapiens (human)
metal ion bindingBromodomain adjacent to zinc finger domain protein 2BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
nucleusBromodomain adjacent to zinc finger domain protein 2BHomo sapiens (human)
chromatinBromodomain adjacent to zinc finger domain protein 2BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (27)

Assay IDTitleYearJournalArticle
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1159589Biochemical screen of P. falciparum MAPK22016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159588Biochemical screen of P. falciparum CDPK42016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159587Biochemical screen of P. falciparum PK72016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159585Biochemical screen of P. falciparum CDPK12016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159586Biochemical screen of P. falciparum PK62016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1065943Binding affinity to human BAZ2B expressed in Escherichia coli BL21(DE3) by STD NMR analysis2013Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
Targeting low-druggability bromodomains: fragment based screening and inhibitor design against the BAZ2B bromodomain.
AID1065942Binding affinity to human BAZ2B expressed in Escherichia coli BL21(DE3) by CPMG NMR analysis2013Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
Targeting low-druggability bromodomains: fragment based screening and inhibitor design against the BAZ2B bromodomain.
AID1065936Displacement of biotinylated H3Kac14 peptide from human BAZ2B expressed in Escherichia coli BL21(DE3) by WaterLOGSY NMR analysis2013Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
Targeting low-druggability bromodomains: fragment based screening and inhibitor design against the BAZ2B bromodomain.
AID1065940Displacement of biotinylated H3Kac14 peptide from His6-tagged human BAZ2B expressed in Escherichia coli BL21(DE3) after 30 mins by AlphaScreen assay2013Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
Targeting low-druggability bromodomains: fragment based screening and inhibitor design against the BAZ2B bromodomain.
AID1708915Binding affinity to HSP90-alpha (unknown origin) expressed in Escherichia coli BL21 by SPR assay2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Discovering High Potent Hsp90 Inhibitors as Antinasopharyngeal Carcinoma Agents through Fragment Assembling Approach.
AID1065941Binding affinity to human BAZ2B expressed in Escherichia coli BL21(DE3) by WaterLOGSY NMR analysis2013Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
Targeting low-druggability bromodomains: fragment based screening and inhibitor design against the BAZ2B bromodomain.
AID1065937Displacement of biotinylated H3Kac14 peptide from human BAZ2B expressed in Escherichia coli BL21(DE3) by CPMG NMR analysis2013Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
Targeting low-druggability bromodomains: fragment based screening and inhibitor design against the BAZ2B bromodomain.
AID1065938Displacement of biotinylated H3Kac14 peptide from human BAZ2B expressed in Escherichia coli BL21(DE3) by STD NMR analysis2013Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
Targeting low-druggability bromodomains: fragment based screening and inhibitor design against the BAZ2B bromodomain.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (28.57)18.7374
1990's1 (7.14)18.2507
2000's1 (7.14)29.6817
2010's6 (42.86)24.3611
2020's2 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.16

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.16 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.87 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.16)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]